197 related articles for article (PubMed ID: 26274064)
1. Antiviral phytochemicals identification from Azadirachta indica leaves against HCV NS3 protease: an in silico approach.
Ashfaq UA; Jalil A; Ul Qamar MT
Nat Prod Res; 2016 Aug; 30(16):1866-9. PubMed ID: 26274064
[TBL] [Abstract][Full Text] [Related]
2. In silico evaluation of inhibitory potential of triterpenoids from Azadirachta indica against therapeutic target of dengue virus, NS2B-NS3 protease.
Dwivedi VD; Tripathi IP; Mishra SK
J Vector Borne Dis; 2016; 53(2):156-61. PubMed ID: 27353586
[TBL] [Abstract][Full Text] [Related]
3. In silico screening for potent inhibitors against the NS3/4A protease of hepatitis C virus.
Meeprasert A; Rungrotmongkol T; Li MS; Hannongbua S
Curr Pharm Des; 2014; 20(21):3465-77. PubMed ID: 24001230
[TBL] [Abstract][Full Text] [Related]
4. Anti-hepatitis C virus activity and synergistic effect of Nymphaea alba extracts and bioactive constituents in liver infected cells.
Rehman S; Ashfaq UA; Ijaz B; Riazuddin S
Microb Pathog; 2018 Aug; 121():198-209. PubMed ID: 29775725
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from
Patil VS; Harish DR; Vetrivel U; Roy S; Deshpande SH; Hegde HV
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164341
[No Abstract] [Full Text] [Related]
6. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF
J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
Ezat AA; Elshemey WM
Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
[TBL] [Abstract][Full Text] [Related]
8. Designing and molecular docking of cyclic peptides against HCV NS3 protease.
Masoud MS; Bukhari SA; Qasim M; Naqvi SAR; Ashfaq UA
Pak J Pharm Sci; 2017 Sep; 30(5(Supplementary)):1965-1969. PubMed ID: 29105629
[TBL] [Abstract][Full Text] [Related]
9. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening.
Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME
J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413
[TBL] [Abstract][Full Text] [Related]
10. Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach.
Palanisamy N; Lennerstrand J
Interdiscip Sci; 2018 Mar; 10(1):143-156. PubMed ID: 27311576
[TBL] [Abstract][Full Text] [Related]
11. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the inhibitory effect of eight compounds from
Wei Y; Yang J; Kishore Sakharkar M; Wang X; Liu Q; Du J; Zhang JJ
Nat Prod Res; 2020 Jun; 34(11):1607-1610. PubMed ID: 30449158
[TBL] [Abstract][Full Text] [Related]
13. A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors.
Takaya D; Yamashita A; Kamijo K; Gomi J; Ito M; Maekawa S; Enomoto N; Sakamoto N; Watanabe Y; Arai R; Umeyama H; Honma T; Matsumoto T; Yokoyama S
Bioorg Med Chem; 2011 Nov; 19(22):6892-905. PubMed ID: 21992802
[TBL] [Abstract][Full Text] [Related]
14. Discovery of small molecule inhibitors against the NS3/4A serine protease of Hepatitis C virus genotype 3 via highthroughput virtual screening and in vitro evaluations.
Sakhor W; Teoh TC; Yusof R; Lim SK; Razif MFM
Trop Biomed; 2020 Sep; 37(3):609-625. PubMed ID: 33612776
[TBL] [Abstract][Full Text] [Related]
15. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
Lee JC; Yu MC; Lien TW; Chang CF; Hsu JT
Assay Drug Dev Technol; 2005 Aug; 3(4):385-92. PubMed ID: 16180993
[TBL] [Abstract][Full Text] [Related]
16. In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening.
Wadood A; Riaz M; Uddin R; Ul-Haq Z
PLoS One; 2014; 9(2):e89109. PubMed ID: 24551230
[TBL] [Abstract][Full Text] [Related]
17. Interactions of ketoamide inhibitors on HCV NS3/4A protease target: molecular docking studies.
Wadood A; Riaz M; Jamal SB; Shah M
Mol Biol Rep; 2014 Jan; 41(1):337-45. PubMed ID: 24234753
[TBL] [Abstract][Full Text] [Related]
18. Rational drug discovery: Ellagic acid as a potent dual-target inhibitor against hepatitis C virus genotype 3 (HCV G3) NS3 enzymes.
Lim SK; Othman R; Yusof R; Heh CH
Chem Biol Drug Des; 2021 Jan; 97(1):28-40. PubMed ID: 32657543
[TBL] [Abstract][Full Text] [Related]
19. Computational Modelling in Studies for Hepatitis C Virus (HCV) NS3 Protease.
Mukhametov A
Curr Top Med Chem; 2016; 16(12):1351-61. PubMed ID: 26585936
[TBL] [Abstract][Full Text] [Related]
20. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.
Matthew AN; Zephyr J; Nageswara Rao D; Henes M; Kamran W; Kosovrasti K; Hedger AK; Lockbaum GJ; Timm J; Ali A; Kurt Yilmaz N; Schiffer CA
mBio; 2020 Mar; 11(2):. PubMed ID: 32234812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
